Skip to content
Screener

Travere Therapeutics, Inc. TVTX Business Segments — Income Tax Expense (Benefit)

Similar metrics at other companies

Sonida Senior Living logo
SNDAReportable Segment — Income Tax Expense (Benefit)
$208K+177%
APO
APOGReportable Segment — Income Tax Expense (Benefit)
$4.4M-13.6%
Mama's Creations, Inc. logo
MAMAReportable Segment — Income Tax Expense (Benefit)
$577K+106%
Rimini Street, Inc. logo
RMNIReportable Segment — Income Tax Expense (Benefit)
$949K-77.7%
Krystal Biotech, Inc. logo
KRYSReportable Segment — Income Tax Expense (Benefit)
$5.51M-29.9%
ImmunityBio, Inc. logo
IBRXReportable Segment — Income Tax Expense (Benefit)
$9K+104%

Other financials

Income statement

See full
Revenue$127.2M+55.6%
Gross profit$125.2M+62.5%
Operating income-$36.9M+13.5%
Net income-$37.1M+10.0%
EPS (diluted)-$0.40+14.9%

Balance sheet

See full
Cash & equivalents$78.4M+26.6%
Total debt$15.6M-82.6%
Total equity$98.7M+201%
Total assets$555.2M+1.2%

Cash flow

See full
Operating cash flow-$40.4M+4.3%
CapEx$140.0K
Free cash flow-$42.5M+28.1%

Valuation

See full
Market cap$5.89B+284%
Enterprise value$5.82B+277%
P/S11×+6.4×

Profitability

See full
Gross margin98.6%+2.6pp
Operating margin-10.6%-5.0pp
Net margin-20.3%-9.5pp
FCF margin-133.9%-34.4pp

Returns & leverage

See full
Return on equity-706%-1,302pp
Debt / equity0.2×-2.6×
Current ratio3.1×+1.1×

Where this comes from

Reported directly by Travere Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.

The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 4:45 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001438533-26-000042
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other research and development4,8414,432
Total research and development57,09446,889
Selling, general and administrative80,25460,413
Royalty expense24,81612,425
Total other income, net1931,487
Income tax benefit (provision)120(39)
Loss from discontinued operations, net of tax(500)
Net loss$(37,102)$(41,226)

Item 1. Financial Statements

FAQ

What is Travere Therapeutics, Inc.'s business segments — income tax expense (benefit)?
Travere Therapeutics, Inc. (TVTX) reported business segments — income tax expense (benefit) of -$120K in Q1 2026.
How has Travere Therapeutics, Inc.'s business segments — income tax expense (benefit) changed year-over-year?
Travere Therapeutics, Inc.'s business segments — income tax expense (benefit) decreased by 407.7% year-over-year, from $39K to -$120K.
What is the long-term trend for Travere Therapeutics, Inc.'s business segments — income tax expense (benefit)?
Over 2 years (2022 to 2025), Travere Therapeutics, Inc.'s business segments — income tax expense (benefit) has grown at a 77.7% compound annual growth rate (CAGR), from $313K to $988K.
What does business segments — income tax expense (benefit) mean?
This metric represents the tax obligations or credits recognized by the company based on its taxable income or losses within the reporting period. It reflects the impact of the company's tax strategy and jurisdictional tax environment on its bottom line.

Ask your AI about Travere Therapeutics, Inc.'s business segments — income tax expense (benefit).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude